Cargando…
Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy
Autores principales: | Muz, Barbara, Azab, Feda, Fiala, Mark, King, Justin, Kohnen, Daniel, Fogler, William E., Smith, Ted, Magnani, John L., Vij, Ravi, Azab, Abdel Kareem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702213/ https://www.ncbi.nlm.nih.gov/pubmed/31431613 http://dx.doi.org/10.1038/s41408-019-0227-3 |
Ejemplares similares
-
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271
por: Natoni, A, et al.
Publicado: (2017) -
AML-337: Targeting E-Selectin with GMI-1271 Overcomes Microenvironment-Mediated Resistance to Venetoclax/HMA Therapy
por: Chang, Kyung Hee, et al.
Publicado: (2020) -
Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth
por: Festuccia, Claudio, et al.
Publicado: (2019) -
Use of GMI‐1271, an E‐selectin antagonist, in healthy subjects and in 2 patients with calf vein thrombosis
por: Devata, Sumana, et al.
Publicado: (2020) -
Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia
por: Wun, Ted, et al.
Publicado: (2014)